Luminex’s xMAP® Technology combines advanced fluidics, optics, and digital signal processing with proprietary microsphere technology to deliver multiplexed assay capabilities. Featuring a flexible, open-architecture design, xMAP Technology can be configured to perform a wide variety of protein or nucleic acid assays quickly, cost-effectively and accurately.
Open-architecture xMAP Technology enables multiplexing of biological tests (assays), reducing time, labor, and costs over traditional methods such as ELISA, western blotting, PCR, and traditional arrays. Systems using xMAP Technology perform discrete assays on the surface of color coded beads known as microspheres, which are then read in a compact analyzer. Using multiple lasers or LEDs and high-speed digital-signal processors, the analyzer reads multiplex assay results by reporting the reactions occurring on each individual microsphere.
Due to robust multiplexing, xMAP Technology potentially delivers more data in less time than other bioassay products, with comparable results to ELISA and Microarray. The technology offers several other distinct advantages over traditional methods:
Importantly, no other solution addresses the needs of applications requiring both a high plex and high throughput at the same time. Traditional ELISA, real-time PCR and other technologies that excel at high throughput applications (greater than 1000 samples per day) lack the ability to multiplex more than five tests at a time. On the other hand, microarray technology excels in high density screening (greater than 250-plex tests) — but lacks the reproducibility needed for high throughput applications. For applications requiring a throughput of up to 1000 samples per day and multiplexing from one to 500 tests per sample, xMAP Technology stands virtually alone.